MMV is working in partnership with GSK to develop tafenoquine, a single-exposure anti-relapse medicine.
GSK is also working with the Foundation for Appropriate Technologies in Health (PATH) to develop a new diagnostic.
2. Howes RE et al. “G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map.” PLoS Med. 9(11): e1001339 (2012).